Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by Mole101on Apr 03, 2021 7:23pm
227 Views
Post# 32934424

From a poster in another board ....

From a poster in another board ....@WishfulThinking I see by some of the content to todays posts that people are taking umbrage with certain comments made by some kinda a gunslinger/ hooligan/outcast. Based on what I see in those posts (Mole101 & Garbage) it appears this "Gangster" is shorting the stock, in my opinion, trying to manipulate others on this board to sell, so he/she can swoop in and make a killing, at their expense. The false narratives "it" is spewing, seems pretty clear to what his/her mandate is. "It" also thinks that there is some kind of conspiracy at play, with BioPub members and the rest of the non-BioPub shareholders, and that if you are a BioPub member, you are getting access to inside information. Funny...as a BioPub subscriber since inception, I recall many of the webcasts made available to anyone to partake, paid subscribers or not. Not every webcast is made available...why sign-up if so. Let's call a spade a shovel...who thinks for a minute, that paid members don't share links to BioPub information to friends and relatives that aren't paid members. Don't be that naive. Having said that, I read the NR that was released the other day. I just finished listening to the webcast from yesterday. There was NO insider information, or SPECIAL instructions, of anything that was not included in the News Release. What struck me about the discussion on the webcast was the genuineness of CM in telling the audience that (paraphrasing) "We are complexed about certain parts of the data...we deliberately did not want to exaggerate the results for sake of feigning a successful study...we are continuing to analyse the data, and are seeking other sources to assist with that interpretation." For some hooligan to think something is so untoward to launch legal action for the "perceived" wrong doing by Algernon management is just farcical...and clearly states the "shorting" intentions, in my view
<< Previous
Bullboard Posts
Next >>